Ergotamine tartrate is used in the therapeutic domain of vascular headache episodes, which includes migraine and cluster headache.

What Ergotamine Tartrate Treats: Main Uses and Benefits

Ergotamine tartrate is applied as an acute, abortive treatment for severe, recurrent vascular headaches, targeting established episodes of migraine and certain forms of cluster headache. It is relevant in situations where symptoms become difficult to tolerate or interfere with daily functioning. It contributes to interrupting the acute progression of the attack and offers supportive symptomatic relief from the intense, throbbing pain.

The medication may also assist in easing the overall burden of associated symptoms, such as nausea, vomiting, photophobia (light sensitivity), and phonophobia (sound sensitivity). This supportive relief helps to ease the overall symptom load and may assist with maintaining functional stability during symptomatic phases.

“The therapeutic approach is relevant for acute episodes associated with heightened physiological activity or temporary physiological imbalance.”

It is commonly used in clinical settings that involve acute or unstable symptom patterns where supportive symptom management is appropriate, or in scenarios requiring additional symptomatic assistance.

Regulatory References

1. NIH DailyMed official drug label

Eligibility Profile: Who Can and Cannot Use Ergotamine Tartrate

This section outlines the official eligibility and non-eligibility requirements for Ergotamine Tartrate, based strictly on government regulatory documents.

Mandatory Contraindications (Must Not Use)

Ergotamine Tartrate is contraindicated in specific populations and conditions due to the risk of severe complications, primarily related to its potent vasoconstrictive effects.

• Cardiovascular and Vascular Disease: Patients with Coronary Heart Disease, Peripheral Vascular Disease, or inadequately controlled hypertension must not use this medicine.
• Metabolic and Systemic Health: Use is forbidden in patients with severe hepatic or renal impairment, sepsis, or known hypersensitivity to ergot alkaloids.
• Reproductive Status: The medicine is contraindicated in women who are or may become pregnant and in nursing mothers.
• Drug Interactions: Concomitant use with potent CYP3A4 inhibitors (e.g., certain macrolide antibiotics or protease inhibitors) and other vasoconstrictor agents (including triptans) is strictly forbidden.

Eligibility Restrictions and Not Established Use

• Age-Related Use: Safety and efficacy are not established for the pediatric population. Caution is advised for the geriatric population.
• Administration Limits: Use is restricted to acute treatment; chronic or continuous use is not recommended due to safety concerns.

The interaction profile of Ergotamine tartrate is characterized by two critical domains: pharmacokinetic interference and pharmacodynamic effects. Co-administration with agents that interfere with its clearance is formally prohibited. This includes potent inhibitors of the CYP3A4 enzyme, such as macrolide antibiotics (e.g., erythromycin, clarithromycin), certain azole antifungals (e.g., ketoconazole, itraconazole), and HIV protease inhibitors. The metabolic inhibition by these agents drastically increases ergotamine plasma concentrations, leading to a severe risk of vasospasm (ergotism).

Due to potent vasoconstrictive properties, ergotamine tartrate is also formally contraindicated with other ergot alkaloids (e.g., dihydroergotamine) and with Triptans (e.g., sumatriptan). This is to prevent potentially dangerous additive vascular effects. A mandatory 24-hour separation is required between the administration of ergotamine and triptans to mitigate this risk.

A documented drug–food interaction exists with grapefruit juice, which acts as a CYP3A4 inhibitor and may also increase the drug's plasma exposure. Furthermore, patients with severe hepatic or renal impairment have a heightened risk of serious interaction outcomes due to their reduced ability to clear the drug from the body.

Ergotamine tartrate acts through a complex, dual mechanism that involves simultaneous modulation of the vascular and neuronal components of the trigeminovascular system. Its action is based on non-selective agonism across multiple monoamine receptor systems, including serotonin and adrenergic targets.

Vascular Tone Modulation and Receptor Agonism

This domain covers the drug's activity on 5- HT1 B serotonin receptors and alpha-adrenoceptors on blood vessel walls. Activation of these receptors causes pronounced and sustained vasoconstriction in the extracerebral arteries, directly countering the extracerebral arterial dilation. This effect is a primary physiological consequence that increases vascular tone.

Inhibition of Neurogenic Signaling

This block describes the drug's action on the neuronal pathways of the trigeminal system, specifically targeting 5- HT1 D receptors on nerve endings. Agonism at these presynaptic sites inhibits the release of pro-inflammatory neuropeptides like CGRP. This neuro-inhibitory cascade dampens the neuro-inflammatory signaling associated with neuropeptide release.

Mechanistic Constraints and Action Duration

The mechanism is defined by the drug's non-selective binding profile, which means its vasoconstrictive effect is not confined solely to the cranial vasculature, extending to peripheral arteries. Furthermore, its functional duration is prolonged by tight tissue binding kinetics and slow receptor dissociation, which results in prolonged receptor occupancy long after typical plasma clearance.

Official Administration Guidelines for Ergotamine Tartrate

Ergotamine tartrate is prescribed for the acute treatment of migraine attacks and must be used strictly according to official instructions to prevent adverse effects and medication overuse headache.

Administration Protocol

Standard Labeled Dosing and Limits

The medication is to be taken at the first sign of a migraine attack. It is not intended for the prevention of migraines or for chronic daily use.

• Initial Dose (Adults): The typical starting dose is 2 mg of Ergotamine Tartrate (or the equivalent combination dose with caffeine).
• Repeat Dosing: If the initial dose does not provide sufficient relief, a follow-up dose (e.g., 2 mg) may be taken after a minimum interval of 30 minutes (oral/sublingual) or 1 hour (rectal).
• Maximum per 24 Hours: Do not exceed a total of 6 mg of Ergotamine Tartrate.
• Maximum Weekly Dose: The strict limit for total weekly intake is 10 mg of Ergotamine Tartrate.

Special Constraints

The most critical restriction is the maximum weekly use limit. This constraint is mandatory to prevent the development of drug dependence, rebound headaches, and the risk of ergotism. The drug is administered on an as-needed basis only, not on a scheduled daily regimen.

Evidence for Use in Acute Migraine Attacks

Research exploring this medicine's use for acute migraine episodes has largely involved older, short-term randomized controlled trials (RCTs) in adult patients. These studies focused on measuring changes in headache pain intensity and the concurrent measurement of associated symptoms, such as nausea and vomiting. Findings describe patterns observed in the trials; however, some trials reported mixed findings when compared to placebo.

Long-term outcomes regarding sustained results or durability of measured effects are not fully established because follow-up durations were limited to single-dose or very short-term treatment phases.

Evidence for Use in Acute Cluster Headaches

Research examined the drug for acute cluster headache attacks through a limited number of controlled trials, with support from decades of documented clinical observation. Studies primarily monitored changes in the severity of the headache episode. The overall body of controlled evidence for this indication is small, and there remains a notable scarcity of robust, high-power controlled trials conducted to modern methodological standards.

Research Gaps and Uncertainties

The current research base primarily focuses on adults from early trials, leading to limited data for specific patient groups. Limited information for long-term outcomes is available for older adults, and dedicated studies assessing the drug in pediatric populations have not been performed.

Studies also include observational data that describes clinical patterns of use and discontinuation in adults with Medication-Overuse Headache. Overall, the evidence quality varies across studies due to the older nature of many trials, and certainty remains low regarding the full range of outcomes after repeated, long-term administration.

Key Studies & References

1. Self-Administered Drug Treatments for Acute Migraine Headache - Executive Summary (AHRQ)

Common questions about Ergotamine tartrate (FAQ)

Q: What is Ergotamine tartrate used for?

Regulatory documents state that Ergotamine tartrate is indicated for the prevention or abortion of vascular headaches, such as migraine and cluster headaches. It is typically used for headaches that have not adequately responded to simpler, non-narcotic pain relievers.

Q: How does Ergotamine tartrate work to treat headaches?

According to the official product information, Ergotamine tartrate belongs to the ergot alkaloid class. It is understood to work by causing the constriction (narrowing) of certain blood vessels in the head and periphery. This action is thought to counteract the extreme vasodilation (widening of blood vessels) associated with vascular headaches, potentially leading to pain relief.

Q: Can Ergotamine tartrate be used to prevent a migraine?

Official information indicates that Ergotamine tartrate is intended for the prevention of vascular headaches when simpler therapy is considered inadequate. It is also designated to 'abort' or stop a migraine once it has begun, especially when administered early during the headache phase.

Q: Is Ergotamine tartrate a narcotic or opioid?

Regulatory documents classify Ergotamine tartrate as an ergot alkaloid, which is a specific class of medication that interacts with certain receptors and blood vessels. It is not classified as a narcotic or an opioid pain reliever.

Q: What does regulatory information state about managing the use of Ergotamine tartrate?

Official regulatory information indicates that this medication is typically not used on a fixed schedule but is taken at the onset of symptoms. The official prescribing information details how the medication is to be used relative to headache symptoms and strictly mandates adherence to specific maximum dose limits. This information is critical to ensure proper use.

Q: How quickly does Ergotamine tartrate start to work?

Official prescribing information emphasizes the importance of early administration in the course of a headache for maximizing the effectiveness of Ergotamine tartrate. The time to onset of relief is noted to vary based on the specific dosage form and individual response to the medication.

Q: Can Ergotamine tartrate cause rebound headaches?

Regulatory documents state that prolonged or excessive use of ergotamine-containing preparations can lead to 'ergotamine-dependent headache.' This condition is a type of medication-overuse headache. Official labeling contains specific warnings regarding the excessive use of this class of medication and emphasizes the importance of following recommended use limits.

Ergotamine tartrate tablets must be stored at Controlled Room Temperature, which is 20 to 25 C (68 to 77 F), with permitted excursions. The medication must be protected from light and stored in a tight, light-resistant container to preserve its potency. Avoid exposing the product to excessive heat or moisture. It is a mandatory requirement to keep this medicine out of the reach of children. For disposal, unused or expired Ergotamine tartrate should be returned through a community drug take-back program. If a program is unavailable, federal guidelines recommend mixing the medicine with an undesirable substance, such as dirt or used coffee grounds, placing the mixture in a sealed container, and discarding it in the household trash. This procedure helps prevent misuse.